Profile: ImmunoGen Inc (IMGN.OQ)
ImmunoGen, Inc., incorporated on March 27, 1981, is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. It has also entered into a collaboration with Merck, under which Merck is focused on providing Keytruda (pembrolizumab) for evaluation in combination with mirvetuximab soravtansine as part of the FORWARD II study. The Company has built a platform that continues to generate ADCs, including IMGN779, its CD33-targeting product candidate for acute myeloid leukemia (AML). IMGN779 integrates one of its deoxyribonucleic acid (DNA)-alkylating IGN payload agents and is progressing through dose escalation in a Phase I trial in AML. It is also advancing IMGN632, a preclinical CD123-targeting ADC that uses IGN payload agent with a new engineered linker and an antibody, which it is developing for hematological malignancies, including AML.
The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4. The Company and its partners utilize its maytansinoid technology in Kadcyla, mirvetuximab soravtansine, anetumab ravtansine, and all other ADCs in development. It also has developed a new class of DNA-acting payload agents, its indolino-benzodiazepines, which it calls IGNs. Its IMGN779 and IMGN632 product candidates utilize its IGN payload agents. The Company's CD33-targeting IMGN779 product candidate for AML is the first ADC to use one of its new IGN payload agents that alkylate DNA without cross-linking it. It has advanced IMGN779 into Phase I clinical testing for AML. Its CD37-targeting ADC, IMGN529, has demonstrated single-agent activity in relapsed/refractory DLBCL in Phase I testing and striking synergy with rituximab in preclinical testing. IMGN529 is in Phase II clinical testing in combination with rituximab. Its other enabling technologies in its portfolio include its array of stable engineered linkers, which direct the release and activation of the payload agent inside the cancer cell, alternative methods of site-specific and non-site-specific attachment of payload to antibody, and alternative antibody assessment, engineering and targeting approaches. In addition, it is collaborating with companies, such as CytomX to gain access to approaches to antibody engineering, such as masking technology.
The Company competes with Pfizer, Seattle Genetics, Roche, Takeda Pharmaceutical Company Limited, AbbVie and Bristol-Myers Squibb.
830 WINTER ST
WALTHAM MA 02451-1477
Company Web Links
- BRIEF-Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer
- BRIEF-Immunogen CFO Johnston buys 10,000 shares of co's common stock on Nov 2
- BRIEF-Immunogen quarterly loss $0.51 per share
- BRIEF-Immunogen: Will reduce workforce by 17 pct
- BRIEF-Immunogen announces update to financial results year ended June 30, 2016 - SEC filing